ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:May 2007
End Date:November 2022

Use our guide to learn which trials are right for you!

A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer

This is a randomised, open label multi-centre phase III study comparing the activity of
lapatinib alone versus trastuzumab alone versus trastuzumab followed by lapatinib versus
lapatinib concomitantly with trastuzumab in the adjuvant treatment of patients with ErbB2
overexpressing and/or amplified breast cancer. Patients will be enrolled according to one of
two design schemas, with Design 2 having two chemotherapy options (Design 2 and 2B), and
will be randomised to one of four treatment regimens within each design schema.

The primary objective of this study is to compare disease-free survival (DFS) in patients
with HER2 overexpressing and/or amplified breast cancer randomised to trastuzumab for one
year versus lapatinib for one year versus trastuzumab (12 or 18 weeks, according to assigned
design) followed by a six-week treatment-free interval followed by lapatinib (28 or 34
weeks, according to assigned design) versus trastuzumab in combination with lapatinib for
one year (52 weeks). Secondary objectives include treatment comparisons with respect to
overall survival, time to recurrence, time to distant recurrence, safety and tolerability,
incidence of brain metastasis, and analyses conducted separately for cohorts of patients
defined by presence or absence of cMyc oncogene amplification, expression level of PTEN and
presence or absence of the p95HER2 receptor. On August 18, 2011, the ALTTO Independent Data
Monitoring Committee (IDMC) met to review the first planned interim analysis. The IDMC
reported that the comparison of lapatinib alone versus trastuzumab alone crossed the
futility boundary, indicating that the lapatinib alone arm was unlikely to meet the
pre-specified criteria to demonstrate non-inferiority to trastuzumab alone with respect to
disease-free survival (DFS). The IDMC also stated that the other three arms (trastuzumab
alone, sequential trastuzumab/lapatinib arm and the combination arm) should continue as
planned with no changes.


Inclusion Criteria:

- Age ≥ 18 years

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;

- Non-metastatic operable primary invasive adenocarcinoma of the breast fulfilling the
following:

1. Histologically confirmed

2. Adequately excised (exceptions: patients who have 'non-resectable' deep margin
invasion are eligible provided they have had or will receive radiotherapy
encompassing the region concerned; patients with histologically documented
infiltration of the skin (pT4) are eligible provided they have undergone or will
receive radiotherapy encompassing the tumour bed);

3. Axilla dissected; sentinel node sampling is allowed provided that axillary
dissection follows confirmation of a positive sentinel node; sentinel node
sampling alone is NOT acceptable after neoadjuvant chemotherapy (in patients
receiving neoadjuvant chemotherapy lymph node status will be considered unknown,
regardless of the results of post-chemotherapy axillary dissection);

4. Axillary node positive patient OR node negative patient with a tumour greater
than or equal to 1.0 cm in greatest diameter. For clarification, isolated tumour
cells (ITC) are considered pN0 and micrometastases are considered pN1

- Known hormone receptor status (ER/PgR or ER alone)

- For Designs 1 and 2: Patients must have received at least four cycles of an approved
anthracycline-based (neo-) adjuvant chemotherapy regimen or listed as an exception in
Table 5 of the protocol.

For Design 1: Randomization must be performed no longer than 12 weeks from day 1 of the
last chemotherapy cycle after obtaining a post-chemotherapy LVEF ≥ 50. Study treatment
must start no more than 14 days after randomization For Design 2: Randomization must be
performed no longer than 6 weeks from day 1 of the last anthracycline-containing
chemotherapy cycle after obtaining a post-anthracycline chemotherapy LVEF ≥ 50. Study
treatment must start no more than 14 days after randomization and must be concurrent with
taxanes.

For Design 2B: Randomisation must be performed no longer than 8 weeks from definitive
surgery. Non-anthracycline platinum containing regimen (docetaxel and carboplatin) and
study treatment must start concomitantly and no more than 14 days after randomisation.

- Baseline LVEF ≥50% measured by echocardiography or MUGA scan. For Design 1 and Design
2 - after completion of all anthracycline-based (neo-) adjuvant chemotherapy and
prior to the targeted therapy(ies); for Design 2B - prior to targeted therapy(ies)
and chemotherapy (docetaxel and carboplatin)

- Over expression and/or amplification of HER2 in the invasive component of the primary
tumour (in case of neoadjuvant treatment, tissue sample used for HER2 testing should
be collected before neoadjuvant treatment starts), according to one of the following
definitions [Wolff et al 2007] and confirmed by central laboratory prior to
randomization:

- 3+ over expression by IHC (> 30% of invasive tumour cells);

- 2+ or 3+ (in 30% or less neoplastic cells) over expression by IHC AND in situ
hybridization (FISH/CISH) test demonstrating HER2 gene amplification;

- HER2 gene amplification by FISH/CISH ( > 6 HER2 gene copies per nucleus, or a FISH
ratio [HER2 gene copies to chromosome 17 signals] of > than 2.2.) Patients with a
negative or equivocal overall result (FISH test ratio of ≤ 2.2, ≤ 6.0 HER2 gene
copies per nucleus) and staining scores of 0, 1+, 2+ or 3+ (in 30% or less neoplastic
cells) by IHC are not eligible for participation in the trial.

Equivocal local results may be submitted for a final determination by the central
laboratory.

- Completion of all necessary baseline laboratory and radiological investigations

- Signed written informed consent (approved by an Independent Ethics Committee (IEC)
and obtained prior to any study specific screening procedures).

Exclusion Criteria:

- History of any prior (ipsi- and/or contralateral) invasive breast carcinoma;

- Past (less than 10 years) or current history of malignant neoplasms, except for
curatively treated 1) basal and squamous cell carcinoma of the skin or 2) carcinoma
in situ of the cervix.

NOTE: Patients with a prior malignancy diagnosed greater than 10 years in the past who
have been curatively treated with surgery ONLY, WITHOUT radiation therapy or systemic
therapy (chemotherapy or endocrine) are eligible for the study. Patients with any prior
diagnosis of breast cancer or melanoma, at any time, are excluded from this study.

- Any clinically staged T4 tumour, including inflammatory breast cancer;

- Bilateral tumours;

- This exclusion criterion has been removed as of protocol amendment 1.

NOTE: multifocal/multicentric tumours are permitted:

- If the patient is node-negative: one of the lesions must be equal or greater than 1.0
cm (sum of the lesion diameters is not acceptable) AND must have positive HER2 status
centrally-confirmed;

- If patient is node-positive: lesion size does not matter BUT one of the lesions must
have HER2 positivity centrally-confirmed. If several lesions are found to be HER2
positive locally, the largest lesion should be considered for central review.

- Maximum cumulative dose of doxorubicin >360mg/m² or maximum cumulative dose of
epirubicin >720mg/m² or any prior anthracyclines unrelated to the present breast
cancer;

- (Neo-) or adjuvant chemotherapy using peripheral stem cell or bone marrow stem cell
support;

- Any prior mediastinal irradiation except internal mammary node irradiation for the
present breast cancer;

- Patients with positive or suspicious internal mammary nodes identified by sentinel
node technique which have not been irradiated or will not be irradiated, or patients
with supraclavicular lymph node involvement (confirmed by fine needle aspirate or
biopsy);

- Prior use of anti-HER2 therapy for any reason or other prior biologic or
immunotherapy for breast cancer;

- Concurrent anti-cancer treatment, except hormonal therapy or radiotherapy for the
present breast cancer;

- Concurrent anti-cancer treatment in another investigational trial with hormone
therapy or immunotherapy unless approved by the Executive Committee:

- Serious cardiac illness or medical conditions including but not confined to:

History of documented congestive heart failure (CHF) or systolic dysfunction (LVEF <50%);
High-risk uncontrolled arrhythmias (ventricular tachycardia, high-grade AV-block,
supraventricular arrhythmias which are not adequately rate-controlled); Angina pectoris
requiring antianginal medication; Clinically significant valvular heart disease; Evidence
of transmural infarction on ECG; Poorly controlled hypertension (e.g. systolic >180mm Hg
or diastolic >100mm Hg);

- Other concurrent serious diseases that may interfere with planned treatment including
severe pulmonary conditions/illness;

- Any of the following abnormal laboratory tests immediately prior to randomization:

serum total bilirubin >1.5 x upper limit of normal (ULN), in the case of known Gilbert's
syndrome, a higher serum total bilirubin (<2 X ULN) is allowed; alanine amino transferase
(ALAT) or aspartate amino transferase (ASAT) >2.5 x ULN; alkaline phosphatase (ALP) > 2.5
x ULN; serum creatinine >2.0 x ULN; total white blood cell count (WBC) <2.5 x 10^9/L;
absolute neutrophil count <1.5 x 10^9/L; platelets <100 x 10^9/L.

- Unresolved or unstable serious adverse events from prior adjuvant chemotherapy or
radiotherapy;

- Malabsorption syndrome, any disease significantly affecting gastrointestinal
function, or resection of the stomach or small bowel, or persons unable to swallow
oral medication. Subjects with ulcerative colitis are also excluded;

- Pregnant, lactating or women of childbearing potential without a negative pregnancy
test - urine or serum - within 7 days prior to randomization, irrespective of the
method of contraception used, including tubal ligation;

- Women of childbearing potential and male participants with partners of child bearing
potential, including women whose last menstrual period was <12 months ago (unless
surgically sterile) who are unable or unwilling to use adequate contraceptive
measures during study treatment (adequate contraceptive measures: intra-uterine
device, barrier method - condoms, diaphragm - also in conjunction with spermicidal
jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are
not indicated in this patient population);

- Concomitant use of CYP3A4 inhibitors or inducers.
We found this trial at
494
sites
Aberdeen, South Dakota 57401
?
mi
from
Aberdeen, SD
Click here to add this to my saved trials
Abilene, Texas 79606
?
mi
from
Abilene, TX
Click here to add this to my saved trials
Abington, Pennsylvania 19001
?
mi
from
Abington, PA
Click here to add this to my saved trials
Adrian, Michigan 49221
?
mi
from
Adrian, MI
Click here to add this to my saved trials
Aiea, Hawaii 96701
?
mi
from
Aiea, HI
Click here to add this to my saved trials
Albert Lea, Minnesota 56007
?
mi
from
Albert Lea, MN
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Alexandria, Minnesota 56308
?
mi
from
Alexandria, MN
Click here to add this to my saved trials
Alton, Illinois 62002
?
mi
from
Alton, IL
Click here to add this to my saved trials
Amarillo, Texas 79106
?
mi
from
Amarillo, TX
Click here to add this to my saved trials
Ames, Iowa 50010
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anderson, South Carolina 29621
?
mi
from
Anderson, SC
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Anthony, Kansas 67003
?
mi
from
Anthony, KS
Click here to add this to my saved trials
Appleton, Wisconsin 54915
?
mi
from
Appleton, WI
Click here to add this to my saved trials
Athens, Georgia 30606
?
mi
from
Athens, GA
Click here to add this to my saved trials
Atlanta, Georgia 30341
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Auburn, Washington 98002
?
mi
from
Auburn, WA
Click here to add this to my saved trials
Augusta, Georgia 30909
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Aurora, Colorado 80010
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Aurora, Illinois 60504
?
mi
from
Aurora, IL
Click here to add this to my saved trials
Austell, Georgia 30106
?
mi
from
Austell, GA
Click here to add this to my saved trials
Austin, Texas 78705
?
mi
from
Austin, TX
Click here to add this to my saved trials
Baltimore, Maryland 21201
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Battle Creek, Michigan 49016
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Beachwood, Ohio 44122
?
mi
from
Beachwood, OH
Click here to add this to my saved trials
Beaumont, Texas 77701
?
mi
from
Beaumont, TX
Click here to add this to my saved trials
Bedford, Texas 76022
?
mi
from
Bedford, TX
Click here to add this to my saved trials
Beech Grove, Indiana 46107
?
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Bellefontaine, Ohio 43311
?
mi
from
Bellefontaine, OH
Click here to add this to my saved trials
Bellingham, Washington 98225
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
Bemidhi, Minnesota 56601
?
mi
from
Bemidhi, MN
Click here to add this to my saved trials
Berazategui, Buenos Aires
?
mi
from
Berazategui,
Click here to add this to my saved trials
Berkeley, California 94704
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
Berlin, Vermont 05602
?
mi
from
Berlin, VT
Click here to add this to my saved trials
Berwyn, Illinois 60402
?
mi
from
Berwyn, IL
Click here to add this to my saved trials
Bethesda, Maryland 20892
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18105
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Bettendorf, Iowa 52722
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Big Rapids, Michigan
?
mi
from
Big Rapids, MI
Click here to add this to my saved trials
Billings, Montana 59102
?
mi
from
Billings, MT
Click here to add this to my saved trials
Bismarck, North Dakota 58501
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
Bloomington, Illinois 61701
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Boca Raton, Florida 33486
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Boise, Idaho 83712
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bolivar, Missouri 65613
?
mi
from
Bolivar, MO
Click here to add this to my saved trials
Boston, Massachusetts 02115
?
mi
from
Boston, MA
Click here to add this to my saved trials
Boulder, Colorado 80304
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Bowling Green, Ohio 43402
?
mi
from
Bowling Green, OH
Click here to add this to my saved trials
Bozeman, Montana 59715
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Bremerton, Washington 98310
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
Bronx, New York 10461
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Bryn Mawr, Pennsylvania 19010
?
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Buffalo, New York 14263
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Burien, Washington 98166
?
mi
from
Burien, WA
Click here to add this to my saved trials
Burlingame, California 94010
?
mi
from
Burlingame, CA
Click here to add this to my saved trials
Burlington, Massachusetts 01805
?
mi
from
Burlington, MA
Click here to add this to my saved trials
Burlington, Vermont 05401
?
mi
from
Burlington, VT
Click here to add this to my saved trials
Burnsville, Minnesota 55337
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
Butler, Pennsylvania 16001
?
mi
from
Butler, PA
Click here to add this to my saved trials
Butte, Montana 59701
?
mi
from
Butte, MT
Click here to add this to my saved trials
Byron Center, Michigan 49519
?
mi
from
Byron Center, MI
Click here to add this to my saved trials
Canton, Illinois 61520
?
mi
from
Canton, IL
Click here to add this to my saved trials
Canton, Ohio 44708
?
mi
from
Canton, OH
Click here to add this to my saved trials
Cape Girardeau, Missouri 63701
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carthage, Illinois 62321
?
mi
from
Carthage, IL
Click here to add this to my saved trials
Casper, Wyoming 82609
?
mi
from
Casper, WY
Click here to add this to my saved trials
Castro Valley, California 94546
?
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Cedar Park, Texas 78613
?
mi
from
Cedar Park, TX
Click here to add this to my saved trials
Cedar Rapids, Iowa 52403
?
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Centralia, Washington 98531
?
mi
from
Centralia, WA
Click here to add this to my saved trials
Chanute, Kansas 66720
?
mi
from
Chanute, KS
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Charleston, South Carolina 29425
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charleston, West Virginia 25304
?
mi
from
Charleston, WV
Click here to add this to my saved trials
Charlottesville, Virginia 22903
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Chattanooga, Tennessee 37421
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Chillicothe, Ohio 54601
?
mi
from
Chillicothe, OH
Click here to add this to my saved trials
Chippewa Falls, Wisconsin 54729
?
mi
from
Chippewa Falls, WI
Click here to add this to my saved trials
Cincinnati, Ohio 45229
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cleveland, Ohio 44195
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clifton Springs, New York 14432
?
mi
from
Clifton Springs, NY
Click here to add this to my saved trials
Clyde, Ohio 43410
?
mi
from
Clyde, OH
Click here to add this to my saved trials
Colorado Springs, Colorado 80910
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Columbia, Ohio 43215
?
mi
from
Columbia, OH
Click here to add this to my saved trials
Columbia, South Carolina 29203
?
mi
from
Columbia, SC
Click here to add this to my saved trials
Columbus, Georgia 31904
?
mi
from
Columbus, GA
Click here to add this to my saved trials
Columbus, Ohio 43219
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Concord, New Hampshire 03301
?
mi
from
Concord, NH
Click here to add this to my saved trials
Coon Rapids, Minnesota 55433
?
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Cooperstown, New York 13326
?
mi
from
Cooperstown, NY
Click here to add this to my saved trials
Coos Bay, Oregon 97420
?
mi
from
Coos Bay, OR
Click here to add this to my saved trials
Dallas, Texas 75230
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Danville, Pennsylvania 17822
?
mi
from
Danville, PA
Click here to add this to my saved trials
Danville, Virginia 24541
?
mi
from
Danville, VA
Click here to add this to my saved trials
Dayton, Ohio 45420
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Dearborn, Michigan 48126
?
mi
from
Dearborn, MI
Click here to add this to my saved trials
Decatur, Georgia 30033
?
mi
from
Decatur, GA
Click here to add this to my saved trials